TG Therapeutics Inc. (NASDAQ:TGTX) – Research analysts at SunTrust Banks reduced their FY2016 EPS estimates for shares of TG Therapeutics in a research note issued to investors on Monday. SunTrust Banks analyst Y. Suneja now anticipates that the firm will post earnings per share of ($1.50) for the year, down from their prior estimate of ($1.27). SunTrust Banks also issued estimates for TG Therapeutics’ Q4 2016 earnings at ($0.39) EPS, Q1 2017 earnings at ($0.40) EPS, Q2 2017 earnings at ($0.35) EPS, Q3 2017 earnings at ($0.36) EPS, Q4 2017 earnings at ($0.37) EPS, FY2017 earnings at ($1.40) EPS, FY2019 earnings at ($1.80) EPS and FY2020 earnings at ($1.90) EPS.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.19. TG Therapeutics had a negative return on equity of 75.52% and a negative net margin of 47,494.08%.

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Other equities analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Roth Capital reiterated a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a report on Tuesday. Brean Capital reiterated a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a report on Thursday, October 6th. Ladenburg Thalmann reiterated a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a report on Saturday, October 15th. Finally, S&P Equity Research dropped their target price on shares of TG Therapeutics from $7.15 to $6.40 in a report on Wednesday, August 24th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $20.86.

TG Therapeutics (NASDAQ:TGTX) opened at 5.60 on Wednesday. The firm’s 50-day moving average price is $6.76 and its 200-day moving average price is $6.87. The company’s market cap is $304.95 million. TG Therapeutics has a 12-month low of $4.90 and a 12-month high of $14.87.

Large investors have recently bought and sold shares of the stock. BlackRock Advisors LLC increased its stake in TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 2,296 shares during the period. Mariner Wealth Advisors LLC increased its stake in TG Therapeutics by 4.4% in the second quarter. Mariner Wealth Advisors LLC now owns 19,086 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 800 shares during the period. BlackRock Group LTD increased its stake in TG Therapeutics by 2.9% in the third quarter. BlackRock Group LTD now owns 17,779 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 504 shares during the period. SECOR Capital Advisors LP bought a new stake in TG Therapeutics during the second quarter valued at $187,000. Finally, Emerald Acquisition Ltd. bought a new stake in TG Therapeutics during the second quarter valued at $190,000. 54.63% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

5 Day Chart for NASDAQ:TGTX

Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.